[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophrenia-spectrum-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophrenia-spectrum-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,59,83,108,134,156,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100637560","using-illusions-to-boost-social-cognition-100637560",false,"NCT07602712","Using Illusions to Boost Social Cognition","Socio-cognitive Benefits of Exposure to Visual Illusions in Patients With Psychotic Disorders","SOLLUSIONS","Inclusion Criteria:\n\n* Aged 18 to 40 years\n* Fluent French speaker\n* Has provided written informed consent\n* For individuals under guardianship (curatorship): inclusion is permitted if the curator is available to assist or advise when needed.\n* Established diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder according to theDiagnostic and statistical manual of mental disorders (DSM-5-TR) criteria\n* Presence of social cognition impairment, defined by:subjective complaint reported by the participant or identified by care teams regarding difficulties in social interaction and clinical confirmation of observable difficulties (e.g., social withdrawal, misinterpretation of others' intentions, inappropriate social behaviour)\n* Membership or entitlement to a social security plan\n\nExclusion Criteria:\n\n* Clinical state incompatible with participation in group-based activities (e.g., severe psychomotor agitation, severe behavioural disturbance)\n* Concurrent participation in another social cognition remediation program\n* Diagnosis of intellectual disability\n* Insufficient comprehension of French for verbal interaction and test completion\n* Significant change in psychotropic medication within the past month\n* Uncorrectable visual impairment preventing participation\n* Pregnant women\n* Individuals under full guardianship (tutorship)","ALL","18 Years","40 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to explore whether the observation of complex visual objects can help improve social cognition in people living with psychotic disorders. Social cognition refers to the ability to understand what others think, feel, or intend, and plays a key role in social relationships and daily interactions.\n\nMain questions this study aims to answer:\n\n* Does dyadic exposure to complex visual objects improve mental state attribution, as measured by the Faux Pas Test?\n* Does the intervention enhance related domains of social cognition, including implicit intention inference (Hinting Task), interpretation of complex interactions (Movie for the Assessment of Social Cognition, MASC), and reduction of hostile attribution biases (Ambiguous Intentions Hostility Questionnaire, AIHQ)?\n* Are improvements maintained after one month, and do patients who receive the intervention later (waitlist group) show the same benefits once exposed?",[28,29],"Schizophrenia Spectrum Disorders","Social Cognition",[31,32,29,33,34,35,36,37,38,39,40,41,42,43,44,45],"Schizophrenia","Psychosis","Mentalizing","Theory of Mind","Cognitive Remediation","Metacognition","Perspective-Taking","Visual Illusions","Viewpoint Illusions","Bottom-Up Intervention","Sensorimotor Rehabilitation","Faux Pas Test","Hinting Task","Social Interaction","Rehabilitation in Psychosis","NOT_YET_RECRUITING","2026-05-19",{"date":49,"type":50},"2026-05-22","ACTUAL",{"date":52,"type":22},"2026-07",{"date":54,"type":22},"2029-02",{"name":56,"class":57},"Hôpital le Vinatier","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":58},"100627999","feasibility-acceptability-and-preliminary-efficacy-of-yoga-based-group-intervention-for-outpatients-with-schizophrenia-spectrum-disorders-100627999","NCT07455929","Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders","Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders (YOGIA Study) - a Three-arm, Single-blind Randomized Controlled Pilot Study","YOGIA","Inclusion Criteria:\n\n* Diagnosis of Schizophrenia Spectrum Disorder by previous (medical) reports according to ICD-10\u002F DSM-V\n* Treated as psychiatric outpatients\n* Age between 18 and 65 years\n* Ability to give informed consent\n* Willingness and ability to engage in psychotherapeutic group therapy\n* Low to moderate psychotic state indicated with a score of ≤ 6 for each item at the Positive scale of the Positive and Negative Syndrome Scale (PANSS, Peralta \\& Cuesta, 1994)\n\nExclusion Criteria:\n\n* Neurological disorders and history of severe traumatic brain injury in the past that may affect cognitive functioning\n* Acute substance dependence, excluding nicotine and prescribed medication\n* PANSS-P score on one item \\> 6 (= very severe)\n* Ineligibility for group participation\n* Acute suicidality, indicated by a score \\> 1 on item 8 of the Calgary Depression Scale for Schizophrenia (Addington, Addington, Maticka-Tyndale, \\& Joyce, 1992)\n* Conflicting co-therapy such as electroconvulsive therapy or ketamine treatment as well as intensive psychotherapy","65 Years",{"count":21,"type":22},[25],"A three-arm pilot rater-blinded randomized controlled trial is conducted, comprising Yoga-based Group Intervention (YoGI + TAU) as the experimental condition, a strength and flexibility training (SFT + TAU) group, and treatment as usual (TAU). Participants in all conditions receive the respective intervention in addition to treatment as usual (TAU) in outpatient settings in Germany. The interventions are designed for patients with schizophrenia spectrum disorders. To examine feasibility, acceptability, and preliminary efficacy, self-report measures and blinded rater-based assessments are administered at baseline (T0), after 12 weeks of participation (T1), and at a 3-month follow-up (T2). Before each intervention session, acute stress (general stress and symptom-related distress) is measured using a visual analogue scale. After each intervention session, acute stress (general stress and symptom-related distress; visual analogue scale), perceived effort (BORG-RPE-Scale), and the occurrence of unpleasant experiences are recorded via self-report, while instructors rate exercise performance and overall participation quality. In addition, semi-structured interviews are conducted at T0 and T1 to assess subjective mechanisms of change and relevant processes.\n\nThe primary outcomes of this trial are the feasibility and acceptability of YoGI and the SFT, assessed through recruitment and retention rates, adherence, and participant feedback. Based on recommendations for pilot studies of 20-50 participants, a conservative target sample size of 60 patients was determined. Further, the trial will evaluate secondary outcomes, including (body) mindfulness (SMQ, BMQ), symptoms of depression, anxiety, and stress (DASS, CDSS), positive and negative symptomatology (PANSS), psychological flexibility (CFQ), psychological well-being (WHO-QoL-BREF), social functioning (PSP), subjectively perceived cognitive functioning (SSTICS), and physical activity (SIMPAQ). This study aims to provide preliminary evidence for the efficacy of YoGI in comparison to both SFT and a TAU, and to establish a foundation for a future fully powered randomized controlled trial.",[72,28],"Psychotic Disorders","RECRUITING","2026-03-09",{"date":76,"type":50},"2026-03-11",{"date":78,"type":22},"2026-03",{"date":80,"type":22},"2028-03",{"name":82,"class":57},"Charite University, Berlin, Germany",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":58},"100623328","acceptability-feasibility-and-preliminary-outcomes-of-the-kiso-mind-app-for-outpatients-with-schizophrenia-spectrum-disorders-100623328","NCT07395206","Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders","Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders: A Randomized Controlled Pilot Trial","KISO","Inclusion Criteria:\n\n* ICD-10: F20 Schizophrenia, F25 Schizoaffective Disorder\n* Age: 18 - 65 years\n* Sufficient German Language Proficiency\n* Ability to Use a Smartphone\n\nExclusion Criteria:\n\n* Intensive Psychotherapy Protocols (more than one psychotherapy session a month)\n* CGI-Score \\\u003C 3; \\> 6\n* No smartphone\n* Neurological Disorders or Brain Damage\n* Acute Suicidality\n* Acute Heavy Substance Abuse or Addiction\n* Current Electroconvulsive Therapy",{"count":21,"type":22},[25],"The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10.\n\nTo examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.",[32,72,95,28,31,96],"Primary Psychotic Disorders","Schizoaffective Disorder",[32,72,95,31,96,28,98,99],"Digital Intervention","E-Health","2026-02-28",{"date":102,"type":50},"2026-03-03",{"date":104,"type":50},"2026-01-30",{"date":106,"type":22},"2026-06-30",{"name":82,"class":57},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":31,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":58},"100619272","gamma-light-and-sound-stimulation-in-schizophrenia-100619272","NCT07342465","Gamma Light and Sound Stimulation in Schizophrenia","Safety, Feasibility, and Preliminary Efficacy of Non-invasive Gamma Neuromodulation in Individuals With Schizophrenia Spectrum Disorders","Inclusion Criteria:\n\n1. Between 18-65 years of age.\n2. A diagnosis of schizophrenia or schizoaffective disorder\n3. No medication is an absolute exclusion. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: the patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS (central nervous system) active drugs.\n4. The subject is willing to sign the informed consent document.\n5. If the subject is deemed not to have the capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n\nExclusion Criteria:\n\n1. Subjects who do not have healthcare\n2. MRI contraindications such as the presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin or body.\n3. High myopia \\\u003C -7 diopters, or untreated cataracts that affect vision.\n4. Clinical conditions:\n\n   1. History of seizure or medical diagnosis of epilepsy.\n   2. ECT history \\> 6 months\n   3. Female subjects who are pregnant or currently breastfeeding.\n   4. Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.\n   5. Significant neurological or medical disorders that may produce cognitive impairment.\n   6. Profound hearing or visual impairment.\n   7. Eye surgery in the last 3 months or are scheduled to have eye surgery in the next 3 months (during the study)",{"count":116,"type":22},20,[25],"Schizophrenia (SZ) is a severe neuropsychiatric disorder impacting over 20 million people globally, causing significant personal and societal burdens, particularly due to cognitive deficits and negative symptoms inadequately treated by current therapies. To address this gap, investigators propose using Gamma Entrainment Using Sensory Stimulation (GENUS), a novel, home-based treatment involving synchronized 40 Hz light-and-sound stimulation aimed at improving neural synchrony, cognition, and SZ symptoms. This innovative approach leverages advanced neurostimulation, biological, and neuroimaging methods to directly target gamma dysfunction, fulfilling an urgent need for effective and accessible at-home therapies.\n\nThe goal of this clinical trial is to learn about the safety and feasibility of gamma stimulation using light and sound. It will also learn if gamma stimulation using light and sound works to treat clinical symptoms and cognitive impairments in schizophrenia. The main questions it aims to answer are:\n\n1. Is gamma stimulation safe for patients with schizophrenia spectrum disorders?\n2. Does gamma stimulation alleviate clinical symptoms and cognitive impairments in schizophrenia patients?\n\nParticipants will:\n\n1. Have an acute 1-hour stimulation at MIT.\n2. Come for a one-day visit to MIT for stimulation, neuroimaging, clinical, and cognitive evaluations.",[28],[121,122,123,124],"schizophrenia","sensory stimulation","gamma stimulation","GENUS","2026-01-23",{"date":127,"type":50},"2026-01-26",{"date":129,"type":22},"2026-04",{"date":131,"type":22},"2027-04",{"name":133,"class":57},"Massachusetts Institute of Technology",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":58},"100612332","a-case-series-of-culturally-adapted-cbtp-for-black-people-in-the-uk-100612332","NCT07252206","A Case Series of Culturally-adapted CBTp for Black People in the UK","Culturally-adapted Cognitive-behavioural Therapy for Black Sub-Saharan African and Caribbean People Experiencing Psychosis: A Case Series","Inclusion Criteria:\n\n* Service users who identify as Black British, Black Caribbean, Black African, African-Caribbean or Mixed African\u002FCaribbean with at least one parent and\u002For grandparent born in a Sub-Saharan African or Caribbean country\n* People with a current ICD-10 schizophrenia spectrum disorder diagnosis, or who are currently receiving or have received support from an Early Intervention in Psychosis team\n* 16 years or older\n* Sufficient understanding of English to complete study measures and engage with CBTp\n\nExclusion Criteria:\n\n* Current, primary diagnosis of substance use disorder\n* Organic aetiology of psychosis\n* Lacking capacity to provide full informed consent\n* Currently experiencing a mental health crisis (i.e., are open to a home-based treatment team; are currently under Section of the Mental Health Act or have been under Section in the past 3 months) or immediate high risk to self or others (i.e., current suicidal intent or plans; unmanaged and intense non-suicidal self-injury)\n* Currently receiving CBTp or received CBTp within the preceding 3 months\n* Unwilling to participate in culturally-adapted CBTp","16 Years",{"count":143,"type":22},6,[25],"The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis. The main question it aims to answer is:\n\nIs culturally-adapted CBT for psychosis feasible, acceptable to and safe for Black Sub-Saharan African and Caribbean people experiencing psychosis?\n\nParticipants will be asked to:\n\n* Answer some questionnaires about how things are at the moment\n* Attend up to 16 sessions of therapy\n* Answer the same questionnaires to see what has changed, if anything\n* Complete a semi-structured interview about their expectations and experience of therapy",[32,28],"2025-11-25",{"date":149,"type":50},"2025-12-03",{"date":151,"type":22},"2026-01",{"date":153,"type":22},"2026-12",{"name":155,"class":57},"University of Manchester",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":172,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":58},"100526692","mi-cbtech-a-mobile-intervention-for-community-integration-in-homeless-experienced-veterans-with-smi-100526692","NCT06138054","MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI","Improving Community Integration in Homeless Veterans With Serious Mental Illness: A Pilot Study of MI-CBT Enhanced With Mobile Technology","Inclusion Criteria:\n\n* Veterans currently residing at the VA Greater Los Angeles Mental Health Residential Rehabilitation Treatment Program (Domiciliary)\n* age 18-65 years\n* diagnosis of non-affective or affective psychotic illness as confirmed by chart review\n* history of homelessness\n* sufficiently fluent in English to consent, understand procedures, and complete assessments and intervention\n* medically and clinically stable (i.e. able to participate in and complete assessments and intervention).\n\nExclusion Criteria:\n\n* history of clinically significant neurological disorder determined by medical history (e.g., epilepsy)\n* history of serious head injury (i.e., loss of consciousness \\> 1 hr, neuropsychological sequelae, cognitive rehabilitation post head injury)\n* evidence of IQ \\\u003C 70 or developmental disability\n* moderate or severe substance use disorder in the past month based on chart review",{"count":164,"type":22},50,[25],"This study aims to test the feasibility and acceptability of a brief behavioral intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral Therapy (CBT), that have been shown to work in prior research studies. The format of the intervention will be a combination of in-person sessions and remote elements delivered via mobile phone (together called MI-CBTech). The goal of the intervention is to improve community integration in Veterans with serious mental illness (SMI) who have experienced homelessness. A time- and format-matched control arm will include remote mindfulness training. 50 Veterans with SMI experiencing homelessness will be randomized to one of the two arms (25 per arm).",[28,168,169,170,171],"Psychotic Affective Disorders","Psychotic Mood Disorders","Homelessness","Ill-Housed Persons",[173,174,175,176,177,178,179,180],"Community Integration","Telerehabilitation","Telemedicine","Cognitive Behavioral Therapy","Motivational Interviewing","Mobile Applications","Smartphone","Smartphone Apps","2025-11-06",{"date":183,"type":50},"2025-11-10",{"date":185,"type":50},"2024-04-01",{"date":187,"type":22},"2026-12-31",{"name":189,"class":190},"VA Office of Research and Development","FED",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":198,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":58},"100511911","neurophysiologic-biomarkers-for-cognitive-rehabilitation-100511911","NCT05945602","Neurophysiologic Biomarkers for Cognitive Rehabilitation","Optimization of Neurophysiologic Biomarkers for Rehabilitation Interventions in Veterans With Chronic Psychosis","Inclusion Criteria:\n\n1. Have a DSM-5 diagnosis of a chronic psychotic disorder (e.g., schizophrenia, schizoaffective disorder, or delusional disorder); or b) are in good general mental and physical health (i.e., no active mental health condition).\n2. Fluent in spoken and written English.\n3. No impairment in hearing or vision.\n\nExclusion Criteria:\n\n1. Active substance other than cannabis within the last 30 days as determined by self-report or positive urine toxicology (obtained as part of the screening process).\n2. History of significant medical or neurological illness or intellectual disability.\n3. Inability to comprehend or provide informed consent.\n4. Specific to healthy comparison subjects: past or present diagnosis of schizophrenia, schizoaffective disorder, or other chronic psychotic disorder.",true,"75 Years",{"count":201,"type":22},80,"OBSERVATIONAL","Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.",[28],[31,206,207],"Schizophrenia Spectrum and Other Psychotic Disorde","Mental Disorders","2025-10-06",{"date":210,"type":50},"2025-10-09",{"date":212,"type":50},"2023-10-01",{"date":214,"type":22},"2028-09-30",{"name":189,"class":190}]